Trial · NCT00589875

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

NCT00589875, Phase 2, Completed, Candel Therapeutics, Inc.; results first posted 2024-04-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma. Trials, record NCT00589875. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00589875

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
NCT number: NCT00589875
Status: Completed
Phases: Phase 2
Enrollment: 52 participants, actual
Lead sponsor: Candel Therapeutics, Inc.
Conditions: Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
Interventions: CAN-2409, Valacyclovir, Temozolomide, Radiation therapy
First posted: 2008-01-10
Last updated: 2024-04-03
Results first posted: 2024-04-03

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Number of Participants With Treatment Related Adverse Events	2 months
Secondary	Overall Survival	5 years
Other	Progression Free Survival	24 months
Other	Functional Assessment of Cancer Therapy - Brain (FACT-Br)	24 months

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Participants With Treatment Related Adverse Events	2 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Overall Survival	5 years	Months	MEDIAN
OTHER_PRE_SPECIFIED	Progression Free Survival	24 months
OTHER_PRE_SPECIFIED	Functional Assessment of Cancer Therapy - Brain (FACT-Br)	24 months

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants With Treatment Related Adverse Events	Single Arm		21		Participants
Overall Survival	Single Arm		18.15	95% Confidence Interval 13.60 to 25.00	Months

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Enrollment to Treatment Initiation	STARTED	Single Arm	52
Enrollment to Treatment Initiation	COMPLETED	Single Arm	43
Enrollment to Treatment Initiation	NOT COMPLETED	Single Arm	9
Treatment Initiation to Completion	STARTED	Single Arm	43
Treatment Initiation to Completion	COMPLETED	Single Arm	36
Treatment Initiation to Completion	NOT COMPLETED	Single Arm	7

Source ClinicalTrials.gov

Adverse events41

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Tinnitus	Ear and labyrinth disorders	Single Arm	3	43
other	Fatigue	General disorders	Single Arm	22	43
other	Fever	General disorders	Single Arm	7	43
other	Alopecia	Skin and subcutaneous tissue disorders	Single Arm	4	43
other	Rash	Skin and subcutaneous tissue disorders	Single Arm	4	43
other	Anorexia	Gastrointestinal disorders	Single Arm	7	43
other	Constipation	Gastrointestinal disorders	Single Arm	9	43
other	Nausea	Gastrointestinal disorders	Single Arm	6	43
other	Taste Alteration	Gastrointestinal disorders	Single Arm	3	43
other	Urinary Tract Infection	Renal and urinary disorders	Single Arm	4	43

1 to 10 of 41Source ClinicalTrials.gov

See all 41 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Single Arm	41	43
Total, other adverse events	Single Arm	40	43
Total, serious adverse events	Single Arm	20	43

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
26843484	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00589875

GET https://conductscience.org/api/trials/v1/NCT00589875/events?page=2

API reference For AI assistants